A phase 1/2A trial of STA 5326, an oral interleukin-12/23 inhibitor, in patients with active moderate to severe Crohn's disease.
Burakoff R, Barish CF, Riff D, Pruitt R, Chey WY, Farraye FA, Shafran I, Katz S, Krone CL, Vander Vliet M, Stevens C, Sherman ML, Jacobson E, Bleday R.
Burakoff R, et al. Among authors: farraye fa.
Inflamm Bowel Dis. 2006 Jul;12(7):558-65. doi: 10.1097/01.ibd.0000225337.14356.31.
Inflamm Bowel Dis. 2006.
PMID: 16804392
Clinical Trial.